Detection of Mutations in the Hepatitis B Virus Polymerase Gene
- 1 June 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 49 (6) , 989-992
Abstract
Antiviral treatment of chronic hepatitis B infection aims to reduce viral replication and/or to affect the immune response to the virus and virus-infected cells. The development of reverse transcriptase inhibitors such as lamivudine, which has been shown to be a safe and potent inhibitor of hepatitis B virus (HBV) replication (1)(2), has facilitated major advances in the antiviral treatment of chronic hepatitis B. Today, lamivudine is a first-line therapy for prophylaxis of HBV recurrence in decompensated cirrhotic patients and liver transplant recipients. A major problem with lamivudine treatment is the emergence of drug resistance, which increases with extended duration of therapy (3). Resistant variants have been localized in the reverse transcriptase ( rt ) region of the HBV polymerase gene. Lamivudine-resistant amino acids have been described at positions rt180 (rtL180M) and rt204 (rtM204V/I/S) (4)(5). Methods for the identification of mutations in the HBV polymerase gene include conventional DNA sequencing, restriction fragment length polymorphism analysis, and reverse hybridization (6)(7). In the past, conventional direct DNA sequencing, which is the gold standard method, was the most labor-intensive and time-consuming method (6). Recently, however, a standardized and largely automated HBV polymerase gene-sequencing assay, the TrugeneTM HBV Genotyping Kit, version 1.0 (Bayer/Visible Genetics, Toronto, Ontario), became commercially available. This assay may be suitable for routine diagnostic laboratory work and clinical trial applications. In this preliminary study, we evaluated the performance of the new HBV genotyping assay. Patients undergoing lamivudine treatment were retrospectively investigated for emergence of specific mutations. Serum samples from five HBV DNA-positive (serum load >1000 HBV DNA copies/mL) patients undergoing lamivudine therapy for more than 6 months were analyzed retrospectively. Blood had been collected in 9.0-mL tubes (VacuetteTM; Greiner Bio-one GmbH), and after centrifugation, sera had been aliquoted and stored at −70 °C. Alanine aminotransferase …Keywords
This publication has 22 references indexed in Scilit:
- Antiviral therapy for hepatitis B virus infections: new targets and technical challengesJournal of Clinical Virology, 2002
- Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapyJournal of Medical Microbiology, 2002
- Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinentJournal of Gastroenterology and Hepatology, 2002
- Enhanced expression of B7-1, B7-2, and intercellular adhesion molecule 1 in sinusoidal endothelial cells by warm ischemia/reperfusion injury in rat liverHepatology, 2001
- Detection of hepatitis B virus resistance to antiviralsJournal of Clinical Virology, 2001
- Extended Lamivudine Treatment in Patients With Chronic Hepatitis B Enhances Hepatitis B E Antigen Seroconversion Rates: Results After 3 Years of TherapyHepatology, 2001
- Hepatitis B virus genotypes and hepatocellular carcinoma in JapanGastroenterology, 2001
- Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase regionHepatology, 2001
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Lamivudine Is Effective in Suppressing Hepatitis B Virus Dna in Chinese Hepatitis B Surface Antigen Carriers: A Placebo–Controlled TrialHepatology, 1997